Combination Casodex® and Iressa™ in locally advanced prostate cancer

Study identifier:1839IL/0129

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized placebo controlled study to assess the rate of PSA decrease, anatomical & metabolic changes in the prostate determined by MRI/3D-MRS & histological changes by biopsy in subjects with locally advanced prostate carcinoma treated with either Casodex® (bicalutamide) alone or the combination of Casodex® & ZD1839 (Iressa™)

Medical condition

Locally advanced prostate cancer

Phase

Phase 2

Healthy volunteers

Study drug

Iressa

Sex

Male

Actual Enrollment

102

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 01 Dec 2003

Primary Completion Date: -

Study Completion Date: 01 Aug 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Trondheim, Norway

Location

Research Site

Oslo, Norway

Location

Research Site

Moelv, Norway

Arms	Assigned Interventions

Documents available

CSR-1839IL-0129.pdf
Download
CSR-1839IL-0129.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca AS Norway

+47 21 00 64 00

Investigators

Principal Investigator

AstraZeneca Norway Medical Director

AstraZeneca AS

Combination Casodex® and Iressa™ in locally advanced prostate cancer

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Documents available

CSR-1839IL-0129.pdf

CSR-1839IL-0129.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator